Role of Home-Based Transcutaneous Electrical Acustimulation for Treatment of Pain in Subjects With Chronic Pancreatitis

NCT ID: NCT06721572

Last Updated: 2026-01-21

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-13
• Study Completion Date: 2026-02-28

Brief Summary

Transcutaneous Electrical Acustimulation (TEA) is a noninvasive acupuncture method that can be self-administered at home without needles. TEA transmits a weak electrical current using electrodes placed at acupoints and has shown to safely reduce pain in other gastrointestinal conditions. This study will help elucidate if TEA is effective in treating abdominal pain in patients with painful chronic pancreatitis (CP).

Detailed Description

Pain in patients with CP is debilitating and impairs quality of life. Despite using medical, endoscopic, or surgical treatments, many patients continue experiencing substantial pain and some are prescribed long-term opioids. This clinical trial aims to assess the analgesic effect of a mild electrical stimulator called TEA. TEA consists of a small, wearable device that can be used at-home while doing daily activities. If effective, this could be an alternative non-pharmacological and non-invasive option to manage pain related to CP.

In this study, the investigators will conduct a randomized, sham-controlled, 2x2 crossover trial in patients with painful CP. Subjects will be randomized to receive either active TEA first followed by sham TEA, or sham TEA first followed by active TEA. Other than the application point in the skin, active and sham TEA will be identical. The study will examine the effect of TEA on pain severity (primary outcome), pain interference and overall pain experience (secondary outcomes). The study will be conducted over 12 weeks in 5 periods: run-in (1 week), treatment period 1 (4 weeks), washout (2 weeks), treatment period 2 (4 weeks), and close-out visit (1 week). Subjects will complete online questionnaires about pain and health throughout the duration of the study. There will be a total of 3 study visits that will be conducted at the main Ann Arbor Hospital or virtually. All the study tasks can be completed remotely. The study will recruit patients from a single clinical center and from self-referral from patients with CP in the US. The proposed study will advance our understanding on the role of TEA for non-opioid pain management of CP.

Conditions

Chronic Pancreatitis; Pancreatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Active TEA first followed by sham TEA

Subjects will undergo active TEA for 4 weeks (week 1-4) followed by a 2-week washout period and then sham TEA for 4 weeks (week 7-10). Subjects will have two instruction visits, one before starting active TEA and one before starting sham TEA.

Group Type: EXPERIMENTAL

TEA

Intervention Type: DEVICE

Active TEA or sham TEA will be self-administered at home over two daily treatment sessions of 30 minutes each in the morning and evening. Active TEA will be delivered through an active stimulation acupoint that has previously shown to reduce abdominal pain in other patient populations. Sham TEA will be administered at a different point a few cm away from the active site and that has been shown to be ineffective in reducing pain. Other than the location, the anatomical location, application of TEA and sham will be identical. The device will be programmed by the study team to generate fixed frequency, pulse width, and time on/time off during the pulsed stimulation. The subject is only able to change the stimulation output in a range from 0-10 milliampere.

Sham TEA first followed by active TEA

Subjects will undergo sham TEA for 4 weeks (week 1-4) followed by a 2-week washout period and then active TEA for 4 weeks (week 7-10). Subjects will have two instruction visits, one before starting active TEA and one before starting sham TEA.

Group Type: EXPERIMENTAL

TEA

Intervention Type: DEVICE

Active TEA or sham TEA will be self-administered at home over two daily treatment sessions of 30 minutes each in the morning and evening. Active TEA will be delivered through an active stimulation acupoint that has previously shown to reduce abdominal pain in other patient populations. Sham TEA will be administered at a different point a few cm away from the active site and that has been shown to be ineffective in reducing pain. Other than the location, the anatomical location, application of TEA and sham will be identical. The device will be programmed by the study team to generate fixed frequency, pulse width, and time on/time off during the pulsed stimulation. The subject is only able to change the stimulation output in a range from 0-10 milliampere.

Interventions

TEA

Active TEA or sham TEA will be self-administered at home over two daily treatment sessions of 30 minutes each in the morning and evening. Active TEA will be delivered through an active stimulation acupoint that has previously shown to reduce abdominal pain in other patient populations. Sham TEA will be administered at a different point a few cm away from the active site and that has been shown to be ineffective in reducing pain. Other than the location, the anatomical location, application of TEA and sham will be identical. The device will be programmed by the study team to generate fixed frequency, pulse width, and time on/time off during the pulsed stimulation. The subject is only able to change the stimulation output in a range from 0-10 milliampere.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Diagnosis of definite or suspected Chronic Pancreatitis (CP). Definite CP features include presence of pancreatic calcifications or Cambridge grade 3-4 on imaging. Suspected CP features include presence of Rosemont criteria suggestive of CP on endoscopic ultrasound or 2 documented attacks of acute pancreatitis separated by at least 1 month without other definite or suspected CP features.
• Abdominal pain that is present for at least 3 months prior to enrollment and having experienced moderate intensity abdominal pain (rated as 4 or higher on a 0-10 Numeric Rating Scale) at least once in the last month.

Exclusion Criteria

• Breastfeeding mother
• Pregnant or intending to become pregnant within the next 3 months
• Incarcerated individuals
• Unwillingness or inability to consent
• Unable to read and speak English precluding completion of questionnaires.
• Familiarity with acupoints that limit blinding
• Currently receiving acupuncture therapy
• Participation in another clinical trial
• Undergoing treatment for cancer or has a suspected or confirmed diagnosis of pancreatic cancer
• Substantial cognitive impairment or mental illness that would prevent providing informed consent and completion of questionnaires.
• Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study
• History of total pancreatectomy with or without islet autotransplantation
• Had during the past month or plan to have within the next 3 months at least one of the following procedures: endoscopic retrograde cholangiopancreatography, pancreatic pseudocyst drainage, celiac plexus block or neurolysis, extracorporeal shock wave lithotripsy, or surgical pancreatic resection or drainage procedure
• Presence of obstructed pancreatic duct that has not yet undergone an attempt for ductal decompression.
• Known allergy to adhesive Electrocardiogram (ECG) electrodes
• History of vagal nerve surgery
• History of bilateral below the knee amputation
• History of lower extremity paralysis
• Presence of an implantable electrical stimulation device

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

American College of Gastroenterology

OTHER

Sponsor Role: collaborator

University of Michigan

OTHER

Sponsor Role: lead

Responsible Party

Jorge Machicado, MD, MPH

Assistant Professor of Internal Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jorge D Machicado, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of Michigan

Locations

University of Michigan

Ann Arbor, Michigan, United States

Countries

United States

Other Identifiers

025780

Identifier Type: OTHER

Identifier Source: secondary_id

HUM00260188

Identifier Type: -

Identifier Source: org_study_id